BioGaia ABBGLAF 100 Return-on-Tangible-Equity is 26.25% as of Mar. 2026, which is 13% above its 10-year median of 23.14. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $13.05 (Fairly Valued). The stock has 5 warning signs investors should review. Among 896 Drug Manufacturers companies, BioGaia AB ranks better than 85.49% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. BioGaia AB's annualized net income for the quarter that ended in Mar. 2026 was $34.1 Mil. BioGaia AB's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $129.9 Mil. Therefore, BioGaia AB's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 26.25%.
The historical rank and industry rank for BioGaia AB's Return-on-Tangible-Equity or its related term are showing as below:
BGLAF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 11.65 Med: 23.14 Max: 57.26
Current: 27.19
During the past 13 years, BioGaia AB's highest Return-on-Tangible-Equity was 57.26%. The lowest was 11.65%. And the median was 23.14%.
BGLAF's Return-on-Tangible-Equity is ranked better than 85.49% of 896
companies
in the Drug Manufacturers industry
Industry Median: 7.795
vs BGLAF: 27.19
BioGaia AB (OTCPK:BGLAF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
BioGaia AB Return-on-Tangible-Equity Related Terms
BioGaia AB Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for BioGaia AB's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BGLAF vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where BioGaia AB's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 26.25% mean?
BioGaia AB (BGLAF) has a Return-on-Tangible-Equity of 26.25% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on BioGaia AB and its competitors. This is 13% above median its historical median of 23.14. Over the past decade, BioGaia AB's Return-on-Tangible-Equity has ranged from 11.65 to 57.26. According to the industry distribution chart, BioGaia AB ranks #130 out of 896 companies in the Drug Manufacturers industry, placing it in the top 14.5%.
Is BioGaia AB's Return-on-Tangible-Equity too high?
BioGaia AB's current Return-on-Tangible-Equity of 26.25% is 13% above median its 10-year median of 23.14. Over the past 10 years, this metric has ranged from a low of 11.65 to a high of 57.26. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.80. BioGaia AB's value of 26.25% is 236.8% above this industry median. Based on the distribution chart, BioGaia AB ranks #130 out of 896 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioGaia AB has a GF Score™ of 100/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #130 out of 896 companies for Return-on-Tangible-Equity. This places BioGaia AB in the top 15% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.80. BioGaia AB's value of 26.25% is 236.8% above this benchmark. Historically, BioGaia AB's own Return-on-Tangible-Equity has ranged from 11.65 to 57.26 over the past decade. While the company's 10-year median is 23.14 vs. the industry median of 7.80, BioGaia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.80, based on 896 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current Return-on-Tangible-Equity of 26.25% is 236.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current Return-on-Tangible-Equity is 26.25%, which is 13% above median its own 10-year median of 23.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
Based on GuruFocus' analysis, BioGaia AB (BGLAF) is currently considered Fairly Valued. The stock's GF Value™ is $13.05, compared to a current price of $12.20 — trading 6.5% below its estimated fair value. The current Return-on-Tangible-Equity is 26.25%, which is 13% above median its 10-year median of 23.14 and 236.8% above the Drug Manufacturers industry median of 7.80. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Return-on-Tangible-Equity is 26.25% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 6.5% below its estimated GF Value™ of $13.05.
GuruFocus considers BioGaia AB to be Fairly Valued.
Key valuation signals for BGLAF:
Return-on-Tangible-Equity: 26.25% (13% above median its 10-year median of 23.14)
GF Value™: $13.05 vs. price of $12.20 (6.5% below fair value)
Industry Position: 236.8% above the Drug Manufacturers median (#130 of 896)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
